Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
OFrontiers in bioengineering and biotechnology · 2023
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors at 6 institutions in 1 country.
Alice CaniPediatric Hematology, Oncology and Stem Cell Transplant Division, Women and Child Health Department, Padua University and Hospital, Padua, Italy.ORCID 0000-0001-8467-2426
Caterina Tretti ParenzanPediatric Hematology, Oncology and Stem Cell Transplant Division, Women and Child Health Department, Padua University and Hospital, Padua, Italy.ORCID 0000-0001-9931-498X
Chiara FrassonOnco-Hematology, Stem Cell Transplant and Gene Therapy, Istituto di Ricerca Pediatrica Foundation - Città della Speranza, Padua, Italy.
Elena RampazzoPediatric Hematology, Oncology and Stem Cell Transplant Division, Women and Child Health Department, Padua University and Hospital, Padua, Italy.ORCID 0000-0002-5232-757X
Pamela ScarparoPediatric Hematology, Oncology and Stem Cell Transplant Division, Women and Child Health Department, Padua University and Hospital, Padua, Italy.
Samuela FrancescatoPediatric Hematology, Oncology and Stem Cell Transplant Division, Women and Child Health Department, Padua University and Hospital, Padua, Italy.
Federico CaicciDiBio Imaging Facility, Department of Biology, University of Padua, Padua, Italy.ORCID 0000-0001-6981-449X
Vito BarbieriDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Antonio RosatoDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.ORCID 0000-0002-5263-8386
Simone CesaroPediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.ORCID 0000-0002-8698-9547
Marco ZeccaPediatric Hematology-Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.ORCID 0000-0002-8818-1744
Concetta MicalizziDepartment of Pediatric Sciences, Istituto Giannina Gaslini, Istituto di Ricovero e Cura a Carattere Scientifico, Genoa, Italy.
Laura SainatiPediatric Hematology, Oncology and Stem Cell Transplant Division, Padua University Hospital, Padua, Italy.ORCID 0000-0002-0441-9496
Martina PigazziPediatric Hematology, Oncology and Stem Cell Transplant Division, Women and Child Health Department, Padua University and Hospital, Padua, Italy.ORCID 0000-0002-4793-5263
Alessandra BiffiPediatric Hematology, Oncology and Stem Cell Transplant Division, Women and Child Health Department, Padua University and Hospital, Padua, Italy.ORCID 0000-0002-4610-0870
Barbara BuldiniPediatric Hematology, Oncology and Stem Cell Transplant Division, Women and Child Health Department, Padua University and Hospital, Padua, Italy.ORCID 0000-0001-7285-2390
Franco LocatelliDepartment of Pediatric Hematology/Oncology and Cell and Gene Therapy, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Pediatrico Bambino Gesù, Department of Pediatrics, Sapienza University of Rome, Rome, Italy.
Luca PersanoPediatric Hematology, Oncology and Stem Cell Transplant Division, Women and Child Health Department, Padua University and Hospital, Padua, Italy.ORCID 0000-0002-0050-3666
Riccardo MasettiPediatric Oncology and Hematology Unit "Lalla Seràgnoli," Pediatric Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum, University of Bologna, Bologna, Italy.ORCID 0000-0002-1264-057X
Geertruij Te KronniePediatric Hematology, Oncology and Stem Cell Transplant Division, Women and Child Health Department, Padua University and Hospital, Padua, Italy.ORCID 0000-0001-5636-1006
Silvia BresolinPediatric Hematology, Oncology and Stem Cell Transplant Division, Women and Child Health Department, Padua University and Hospital, Padua, Italy.ORCID 0000-0001-7677-7084
University of Padua · ITAzienda Ospedaliera Universitaria Integrata Verona · ITBambino Gesù Children's Hospital · ITCittà della Speranza Foundation · ITIstituto Giannina Gaslini · ITUniversity of Bologna · IT
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Juvenile myelomonocytic leukemia (JMML) is a rare clonal stem cell disorder that occurs in early childhood and is characterized by the hyperactivation of the RAS pathway in 95% of the patients. JMML is characterized by a hyperproliferation of granulocytes and monocytes, and little is known about the heterogeneous nature of leukemia-initiating cells, as well as of the cellular hierarchy of the JMML bone marrow. In this study, we report the generation and characterization of a novel patient-derived three-dimensional (3D) in vitro JMML model, called patient-derived JMML Atypical Organoid (pd-JAO), sustaining the long-term proliferation of JMML cells with stem cell features and patient-specific hallmarks. JMML cells brewed in a 3D model under different microenvironmental conditions acquired proliferative and survival advantages when placed under low oxygen tension. Transcriptomic and microscopic analyses revealed the activation of specific metabolic energy pathways and the inactivation of processes leading to cell death. Furthermore, we demonstrated the pd-JAO-derived cells' migratory, propagation, and self-renewal capacities. Our study contributes to the development of a robust JMML 3D in vitro model for studying and defining the impact of microenvironmental stimuli on JMML disease and the molecular mechanisms that regulate JMML initiating and propagating cells. Pd-JAO may become a promising model for compound tests focusing on new therapeutic interventions aimed at eradicating JMML progenitors and controlling JMML disease.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Long-term proliferation of immature hypoxia-dependent JMML cells supported by a 3D in vitro system. · full record | OpenQuestion